We examine key peptides, current evidence, and what you should consider before starting any regimen
NICE technology appraisal guidance TA875 recommends semaglutide for use within specialist weight management services, subject to specific eligibility criteria: a BMI of 35 kg/m or above, or a lower BMI threshold for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds, alongside at least one weight-related comorbidity, and as part of a specialist multidisciplinary programme
Hives may be its first visible sign, but the defining features are systemic: throat tightness, shortness of breath or wheezing, dizziness, rapid or weak pulse, and a sudden drop in blood pressure
It is not a medicine, food, supplement, cosmetic, or medical device, and is not for human or veterinary use, administration, or consumption